Ambev Short Interest Falls Further as Options Turn Cautious

Short sellers have continued to exit ABEV in the days since the previous ORTEX preview. Positions have dropped a further 8.8% in a single session to 81.8 million shares, down 43% over the past month, the lowest level recorded in the ORTEX dataset. The retreat has been sharp and sustained: from roughly 136 million shares in early October to below 82 million now, with the bulk of that unwind happening in just three weeks. Availability has tightened sharply from that loosened state, moving to 90.6% from 174% a week ago, meaning the lending pool has become meaningfully more competitive even as fewer shares are borrowed. Cost to borrow remains modest at 1.16%, up 4% on the week but far below the spike above 7.6% seen in late September. The contrast with that episode matters: borrow is still cheap, and the recent tightening in availability reflects a shift in the pool size rather than a scramble for shares.

Options positioning is the more cautious signal going into the print. The put/call ratio jumped to 0.51 on Tuesday, more than two standard deviations above its 20-day average of 0.40. That is the most defensive options lean in the recent period, and it sits against the backdrop of a stock that has fallen 13.6% over the past week to $2.87, even after recovering 1.4% on Tuesday.

The analyst backdrop reinforces the caution. B of A Securities downgraded ABEV to Underperform on October 7, keeping its $3.30 target, which now sits about 15% above the current price. UBS holds a Sell rating with a $2.90 target. Scotiabank also stepped down to Sector Perform in July. Barclays is the relative outlier, maintaining Equal-Weight with a $3.50 target after raising it twice this year. The direction of travel across the Street has been negative, with multiple downgrades since mid-2025 and no upgrades in the same window. ABEV's factor scores reflect that tension: the dividend score ranks in the 94th percentile and the EPS surprise score in the 81st, pointing to a company that has historically beaten estimates and returns cash, but the forward earnings growth score ranks just 26th, and the ORTEX short score sits at a neutral 50.4.

Ownership is tightly held. Anheuser-Busch InBev controls 63% of shares, and the next largest disclosed holder, Fundacao Antonio e Helena Zerrenner, holds a further 10%. The free float available to outside investors is correspondingly thin, which helps explain why even a moderate short position can move availability metrics meaningfully. Insider activity over the past 90 days has been modestly negative on net, with a director selling $1.4 million in late July and a separate sale of $188,000 in September, both open-market transactions outside any pre-arranged plan.

The print arrives with short positioning at a multi-year low, options traders paying up for downside protection, and the analyst consensus having tilted bearish over the course of 2026. What the Q3 numbers will test is whether Ambev's track record of beating estimates is enough to offset the macro concerns about Brazilian consumer demand that drove those downgrades.